Literature DB >> 12429577

Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine.

Anaid Shahbazian1, Akos Heinemann, Bernhard A Peskar, Peter Holzer.   

Abstract

1. Since the role of prostanoid receptors in intestinal peristalsis is largely unknown, the peristaltic motor effects of some prostaglandin (DP, EP, IP), thromboxane (TP) and leukotriene (LT) receptor agonists and antagonists were investigated. 2. Propulsive peristalsis in fluid-perfused segments from the guinea-pig small intestine was triggered by a rise of the intraluminal pressure and recorded via the intraluminal pressure changes associated with the peristaltic waves. Alterations of distension sensitivity were deduced from alterations of the peristaltic pressure threshold and modifications of peristaltic performance were reflected by modifications of the amplitude, maximal acceleration and residual baseline pressure of the peristaltic waves. 3. Four categories of peristaltic motor effects became apparent: a decrease in distension sensitivity and peristaltic performance as induced by the EP1/EP3 receptor agonist sulprostone and the TP receptor agonist U-46619 (1-1000 nM); a decrease in distension sensitivity without a major change in peristaltic performance as induced by PGD(2) (3-300 nM) and LTD(4) (10-100 nM); a decrease in peristaltic performance without a major change in distension sensitivity as induced by PGE(1), PGE(2) (1-1000 nM) and the EP1/IP receptor agonist iloprost (1-100 nM); and a decrease in peristaltic performance associated with an increase in distension sensitivity as induced by the EP2 receptor agonist butaprost (1-1000 nM). The DP receptor agonist BW-245 C (1-1000 nM) was without effect. 4. The peristaltic motor action of sulprostone remained unchanged by the EP1 receptor antagonist SC-51089 (1 micro M) and the DP/EP1/EP2 receptor antagonist AH-6809 (30 micro M), whereas that of U-46619 and LTD(4) was prevented by the TP receptor antagonist SQ-29548 (10 micro M) and the cysteinyl-leukotriene(1) (cysLT(1)) receptor antagonist tomelukast (10 micro M), respectively. 5. These observations and their pharmacological analysis indicate that activation of EP2, EP3, IP, TP and cysLT(1) receptors, but not DP receptors, modulate intestinal peristalsis in a receptor-selective manner, whereas activation of EP1 seems to be without influence on propulsive peristalsis. In a wider perspective it appears as if the effect of prostanoid receptor agonists to induce diarrhoea is due to their prosecretory but not peristaltic motor action.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429577      PMCID: PMC1573581          DOI: 10.1038/sj.bjp.0704958

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract.

Authors:  A Northey; D Denis; M Cirino; K M Metters; F Nantel
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-07       Impact factor: 3.072

2.  Effects of the inflammatory mediator prostaglandin E2 on myenteric neurons in guinea pig ileum.

Authors:  J A Dekkers; L M Akkermans; A B Kroese
Journal:  Am J Physiol       Date:  1997-06

3.  Tachykinin NK1 and NK2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro.

Authors:  P Holzer; I T Lippe; A Heinemann; L Barthó
Journal:  Neuropharmacology       Date:  1998       Impact factor: 5.250

Review 4.  Leukotriene receptors.

Authors:  K M Metters
Journal:  J Lipid Mediat Cell Signal       Date:  1995-10

5.  Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract.

Authors:  K Morimoto; Y Sugimoto; M Katsuyama; H Oida; K Tsuboi; K Kishi; Y Kinoshita; M Negishi; T Chiba; S Narumiya; A Ichikawa
Journal:  Am J Physiol       Date:  1997-03

Review 6.  Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.

Authors:  E W Jonsson
Journal:  Acta Physiol Scand Suppl       Date:  1998-03

Review 7.  Prostanoid receptors: structures, properties, and functions.

Authors:  S Narumiya; Y Sugimoto; F Ushikubi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

8.  Different receptors mediating the inhibitory action of exogenous ATP and endogenously released purines on guinea-pig intestinal peristalsis.

Authors:  A Heinemann; A Shahbazian; L Barthó; P Holzer
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

9.  Analysis of contributions of acetylcholine and tachykinins to neuro-neuronal transmission in motility reflexes in the guinea-pig ileum.

Authors:  P J Johnson; J C Bornstein; S Y Yuan; J B Furness
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

10.  N-substituted dibenzoxazepines as analgesic PGE2 antagonists.

Authors:  E A Hallinan; T J Hagen; R K Husa; S Tsymbalov; S N Rao; J P vanHoeck; M F Rafferty; A Stapelfeld; M A Savage; M Reichman
Journal:  J Med Chem       Date:  1993-10-29       Impact factor: 7.446

View more
  10 in total

1.  Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation.

Authors:  Francesca Borrelli; Francesco Capasso; Raffaele Capasso; Valeria Ascione; Gabriella Aviello; Rocco Longo; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret.

Authors:  Kelvin K W Kan; Man P Ngan; Man K Wai; John A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-11       Impact factor: 3.000

Review 3.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.

Authors:  I Dey; M Lejeune; K Chadee
Journal:  Br J Pharmacol       Date:  2006-10-02       Impact factor: 8.739

4.  Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors.

Authors:  Sorin Tunaru; Till F Althoff; Rolf M Nüsing; Martin Diener; Stefan Offermanns
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  Prostanoid EP3 receptor agonist sulprostone enhances pacemaker activity of colonic interstitial cells of Cajal.

Authors:  Man Woo Kim; Han Yi Jiao; Seok Won Kim; Chan Guk Park; Mei Jin Wu; Chansik Hong; Seok Choi; Jae Yeoul Jun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-06       Impact factor: 3.000

Review 6.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

7.  Role of prostaglandin D2 in mast cell activation-induced sensitization of esophageal vagal afferents.

Authors:  Shizhong Zhang; Gintautas Grabauskas; Xiaoyin Wu; Moon Kyung Joo; Andrea Heldsinger; Il Song; Chung Owyang; Shaoyong Yu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-07       Impact factor: 4.052

8.  Anti-inflammatory Effects of Enhanced Recovery Programs on Early-Stage Colorectal Cancer Surgery.

Authors:  Aurélien Venara; Emilie Duchalais; Anne Dariel; Philippe Aubert; Tony Durand; Guillaume Meurette; Malvyne Rolli-Derkinderen; Antoine Hamy; Michel Neunlist
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

9.  Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.

Authors:  Ralph T Schermuly; Soni S Pullamsetti; Susanne C Breitenbach; Norbert Weissmann; Hossein A Ghofrani; Friedrich Grimminger; Sigrid M Nilius; Karsten Schrör; Jutta M Kirchrath; Werner Seeger; Frank Rose
Journal:  Respir Res       Date:  2007-01-26

10.  Eicosanoid modulation by the short-chain fatty acid n-butyrate in human monocytes.

Authors:  Johannes J Kovarik; Markus A Hölzl; Johannes Hofer; Petra Waidhofer-Söllner; Yury Sobanov; René Koeffel; Marcus D Saemann; Diana Mechtcheriakova; Gerhard J Zlabinger
Journal:  Immunology       Date:  2013-07       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.